CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
This randomized, double blind, phase 2/3 study is aimed to evaluate the efficacy and safety of CM082 in combination with everolimus in Chinese patients with advanced renal cell carcinoma. The primary endpoint is progression-free survival.
Epistemonikos ID: 942e576d12c181f6d7bef7577b4531337c442253
First added on: May 20, 2024